David S. Ritchie

391.9: Real world efficacy of maribavir when used as pre-emptive therapy for cytomegalovirus reactivation in alloHCT patients who are intolerant, refractory or resistant.

Violet Zhu, Michelle K. Yong, Alexandra Rivalland, Catherine Schembri et autres

au (code pays fourni par la source)

Marginal zone lymphoma is associated with dysregulated T-cell immunity that is not altered by ibrutinib-venetoclax treatment

Joanne E. Davis, Lina H.H. Le, Mandy Ludford‐Menting, Nicholas Holzwart et autres

< .05). To our knowledge, this is the first study to examine peripheral blood immunology in MZL as a single disease group. Given the lack of T-cell repair, immunotherapy protocols using ibrutinib may be less effective in MZL. This trial was registered …

au (code pays fourni par la source)

Identification of T:B Cell Multimers After Bispecific T Cell Engagement, Using Both Conventional and Imaging Flow Cytometry

Joanne E. Davis, Mandy Ludford‐Menting, Helena Peng, Darryl N. Johnson et autres

Bispecific T cell engagers bring together T cells with malignant B cell targets to enable synapse formation and disease eradication of hematological malignancies. The proportion of T cells and their ability to bind to their targets varies between patients and may be …

au (code pays fourni par la source)

Pre-transplant azacitidine does not improve survival in allogeneic HSCT for higher-risk MDS

Miles B. Horton, Becky Leung, Ricky Nelles, Matthew Rubic et autres

au (code pays fourni par la source)